Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02654509 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine
A Phase 2 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 2
- Development phase
- 138
- Enrollment target
NCT02654509: Completed Phase 2 study, sponsored by U.S. Army Medical Research and Development Command.
NCT02654509 is a Phase 2 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 138 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02654509, a Phase 2 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 138 participants
- Enrollment target
Study Summary
This study is being conducted to collect safety and immunogenicity data for the Eastern Equine Encephalitis (EEE) vaccine.
Primary Outcome
The determined adverse events after vaccination (1 month) as reported by participants by severity and system organ class.
Interventions
- BIOLOGICAL Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2008-06-03 |
| Est. Completion | 2018-03-18 |
| Phase | Phase 2 |
What the finished NCT02654509 record still lists
NCT02654509 is an interventional study that assigns participants to a tested intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104 is the first listed.
NCT02654509 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02654509 about?
NCT02654509 is a clinical study titled "Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine". This study is being conducted to collect safety and immunogenicity data for the Eastern Equine Encephalitis (EEE) vaccine.
What is the current status of trial NCT02654509?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 138 participants. The study started on 2008-06-03. Estimated completion is 2018-03-18.
What interventions are being tested in trial NCT02654509?
The interventions under investigation include: Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02654509?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02654509's enrollment target sits among peer trials
138 525th of 2000 higher than 1,474 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04402788 · 138 participants · Phase 2
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
- NCT04883255 · 138 participants · Early Phase 1
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
- NCT05620784 · 138 participants · Phase 3
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
- NCT05832086 · 138 participants · Phase 2
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI